Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives

News

 16th May 2011 Cardio3 BioSciences

Cardio3 BioSciences Presents C-Cure® Phase II Clinical Trial Results at the EuroPCR Meeting

Innovative Heart-Specified Stem Cell Therapy Opens a New Chapter in Cardiovascular Regenerative Medicine

Mont-Saint-Guibert, Belgium, May 16, 2011 – The Belgian biotechnology company, Cardio3 BioSciences, a leader in discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, will present Phase II clinical trial data of the flagship product C3BS-CQR-1 (C-Cure®), at the EuroPCR Meeting in Paris on Wednesday, 18th May. This is the first-in-man use of lineage specified stem cells for the treatment of heart failure.

On behalf of the C-Cure international program, data will be presented by Dr. Dariouch Dolatabadi, Civil Hospital, Charleroi, Belgium and Investigator of the C3BS-CQR-1 (C-Cure) trial.

The trial demonstrates that heart failure patients improved heart function and exercise capacity at 6 months following treatment of C-Cure, an innovative stem cell therapy based on the Company’s “Cardiopoiesis” proprietary technology. Moreover, feasibility and safety of the C-Cure treatment regimen were established.

Data strongly suggest that C-Cure is a promising treatment for heart failure, one of the world’s greatest unmet medical needs. A person living to the age of 40 has a one-in-five risk of developing heart failure and, once the disorder is apparent, a one-in-three chances of dying within a year of diagnosis.

More detailed information on www.c3bs.com/fr/products-pipeline/clinical.html


 

Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |